Source-grounded facts extracted from Seres Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Hans-Juergen Woerle resigned as member of the board of directors at Seres Therapeutics, Inc..
“On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the “Company”) and on the committees on which he serves, effective May 31, 2026.”
Seres Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $19.9 million for the first quarter of 2026.
“Seres Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and provided operational updates.”
Lisa von Moltke resigned as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc..
“On February 22, 2025, Lisa von Moltke, M.D. notified Seres Therapeutics, Inc. (the “Company”) of her intention to resign as the Executive Vice President and Chief Medical Officer of the Company, effective as of March 14, 2025.”
Hans-Juergen Woerle, M.D. was appointed as Class III director at Seres Therapeutics, Inc..
“appointed Hans-Juergen Woerle, M.D., as a Class III director of the Company, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.